Free Trial
→ You missed yesterday's deadline… (From Behind the Markets) (Ad)tc pixel
NASDAQ:BRTX

Biorestorative Therapies Q2 2026 Earnings Date & Estimates

Biorestorative Therapies logo
$1.47 -0.01 (-0.68%)
Closing price 03:58 PM Eastern
Extended Trading
$1.50 +0.03 (+1.70%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biorestorative Therapies is estimated to report Q2 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 10, 2026 at 3:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q2 2026
Announcement Date
Conference Call Date
Conference Call
3:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biorestorative Therapies in Q2 2026

Biorestorative Therapies is expected to post earnings of -$1.40 per share on revenue of $650 thousand. In the same quarter a year earlier Biorestorative Therapies reported -$7.60 per share on revenue of $11.80 thousand. Biorestorative Therapies last reported on May 14, 2026, posting -$3.80 per share and beating the -$4.00 consensus estimate. Biorestorative Therapies has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.40
Expected Revenue
$650 thousand
Prior-Year EPS
-$7.60
Prior-Year Revenue
$11.80 thousand
Expected Revenue Growth
+5,408.5%

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
-$3.80 (Beat by +$0.20)
Last Quarter Revenue
$23.17 thousand
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q2 2026 Call

Biorestorative Therapies Q2 2026 Earnings FAQ

Biorestorative Therapies (NASDAQ:BRTX) is estimated to report Q2 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Biorestorative Therapies' Q2 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 3:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Biorestorative Therapies to post earnings of -$1.40 per share for Q2 2026.

The consensus revenue estimate for Biorestorative Therapies is $650 thousand for Q2 2026.

Biorestorative Therapies Earnings Headlines

Maxim Group downgrades BioRestorative Therapies to hold from buy
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/maxim-group-downgrades-biorestorative-therapies-to-hold-from-buy/ar-AA2dIoSm
Maxim Downgrades BioRestorative Therapies to Hold From Buy
October 6, 2026  |  marketscreener.comM
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
November 4 at 1:00 AM  |  Weiss Ratings (Ad)
BioRestorative Therapies (BRTX)
September 29, 2026  |  es.investing.comhttps://es.investing.com/equities/biorestorative-therapies-consensus-estimates
BioRestorative Therapies consensus price target increased by 1,900% to $163.20
September 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/biorestorative-therapies-consensus-price-target-increased-by-1-900-to-163-20/ar-AA2ckvFG
BioRestorative Therapies Announces Reverse Stock Split
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355556/0/en/biorestorative-therapies-announces-reverse-stock-split.html
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX) is a biotechnology company focused on developing regenerative medicine products using cell and tissue-based technologies. The company’s programs are intended to address conditions for which existing treatment options may be limited, including musculoskeletal and metabolic disorders.

Its lead product candidate, BRTX-100, is an autologous cell therapy developed from a patient’s own bone marrow and designed to treat painful lumbar disc disease, including chronic lower-back pain associated with degenerated discs. BioRestorative Therapies has also developed the ThermoStem program, which is focused on using brown adipose-derived stem cells and related technologies for potential applications in obesity and other metabolic disorders.

The company is based in Melville, New York, and its development activities have primarily centered on advancing its regenerative medicine candidates through clinical and preclinical research. BioRestorative Therapies’ programs remain subject to regulatory review and further clinical development before they can become broadly available treatments.

View Biorestorative Therapies Profile
Earnings Tools